Literature DB >> 18925489

Neuropsychiatric symptoms in dementia: importance and treatment considerations.

Clive Ballard1, Sarah Day, Sally Sharp, Gayle Wing, Susanne Sorensen.   

Abstract

Neuropsychiatric symptoms are frequent in people with dementia, result in distress for the people experiencing them and their caregivers, and are a common precipitant of institutional care. The safe and effective treatment of these symptoms is a key clinical priority, but is a long way from being achieved. Psychological interventions are recommended as the first line treatment strategy in most good practice guidelines, and there is emerging evidence of efficacy for agitation and depression. Neuroleptics remain the mainstay of pharmacological treatment, although meta-analyses indicate that they are mainly of benefit for the short-term (up to 12 weeks) treatment of aggression in people with Alzheimer's disease, and there have been increasing concerns about serious adverse effects including mortality. The evidence is limited for other pharmacological approaches for the treatment of agitation, and psychosis in people with Alzheimer's disease is limited, but post-hoc analyses do indicate that memantine may be a promising therapy and aromatherapy may be a useful alternative. Autopsy studies indicate that the adrenergic system may be an important therapeutic target. Clinical experience suggests that antidepressants are effective in people with severe depression in the context of dementia, but the evidence base regarding the broader value of antidepressants is far from clear. There are very few trials specifically focusing upon the treatment of neuropsychiatric symptoms in common non-Alzheimer dementias, which is a major limitation and urgently needs to be addressed to provide an evidence base to enable the safe and effective treatment of these individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925489     DOI: 10.1080/09540260802099968

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  25 in total

1.  Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease.

Authors:  Maria Carmela Tartaglia; Bei Hu; Kala Mehta; John Neuhaus; Kristine Yaffe; Bruce L Miller; Adam Boxer
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Apr-Jun       Impact factor: 2.703

2.  Association of a Communication Training Program With Use of Antipsychotics in Nursing Homes.

Authors:  Jennifer Tjia; Jacob N Hunnicutt; Laurie Herndon; Carolyn R Blanks; Kate L Lapane; Susan Wehry
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

Review 3.  Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.

Authors:  Irene Bolea; Alejandro Gella; Mercedes Unzeta
Journal:  J Neural Transm (Vienna)       Date:  2012-12-13       Impact factor: 3.575

4.  Prevalence and associations of potentially inappropriate prescriptions in Austrian nursing home residents: secondary analysis of a cross-sectional study.

Authors:  Eva Mann; Burkhard Haastert; Birgit Böhmdorfer; Thomas Frühwald; Bernhard Iglseder; Regina Roller-Wirnsberger; Gabriele Meyer
Journal:  Wien Klin Wochenschr       Date:  2013-03-28       Impact factor: 1.704

5.  The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia.

Authors:  Kate de Medeiros; P Robert; S Gauthier; F Stella; A Politis; J Leoutsakos; F Taragano; J Kremer; A Brugnolo; A P Porsteinsson; Y E Geda; H Brodaty; G Gazdag; J Cummings; C Lyketsos
Journal:  Int Psychogeriatr       Date:  2010-07-01       Impact factor: 3.878

Review 6.  New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

Authors:  Salvatore Salomone; Filippo Caraci; Gian Marco Leggio; Julia Fedotova; Filippo Drago
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

7.  PRND 3'UTR polymorphism may be associated with behavioral disturbances in Alzheimer disease.

Authors:  Marcin Flirski; Monika Sieruta; Ewa Golańska; Iwona Kłoszewska; Paweł P Liberski; Tomasz Sobów
Journal:  Prion       Date:  2012 Jan-Mar       Impact factor: 3.931

8.  Consumption of pharmaceuticals in primary non-Alzheimer's degenerative dementias : a cross-sectional study by the Registry of Dementias of Girona (ReDeGi).

Authors:  Secundino López-Pousa; Oriol Turró-Garriga; Laia Calvó-Perxas; Olga Carmona; Jordi Gich; Elisabet Alsina; Fabià Màrquez; Marta Viñas; Josefa Turbau; Joan Vilalta-Franch; Anna Maria Roig; Josep Garre-Olmo
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

9.  The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.

Authors:  Zahinoor Ismail; Luis Agüera-Ortiz; Henry Brodaty; Alicja Cieslak; Jeffrey Cummings; Corinne E Fischer; Serge Gauthier; Yonas E Geda; Nathan Herrmann; Jamila Kanji; Krista L Lanctôt; David S Miller; Moyra E Mortby; Chiadi U Onyike; Paul B Rosenberg; Eric E Smith; Gwenn S Smith; David L Sultzer; Constantine Lyketsos
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 10.  TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease.

Authors:  Filippo Caraci; Giuseppe Battaglia; Valeria Bruno; Paolo Bosco; Viviana Carbonaro; Maria Laura Giuffrida; Filippo Drago; Maria Angela Sortino; Ferdinando Nicoletti; Agata Copani
Journal:  CNS Neurosci Ther       Date:  2009-11-19       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.